<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03279835</url>
  </required_header>
  <id_info>
    <org_study_id>16-PP-09</org_study_id>
    <nct_id>NCT03279835</nct_id>
  </id_info>
  <brief_title>Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients</brief_title>
  <acronym>NEURACog</acronym>
  <official_title>Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective study is to evaluate the prevalence of neurocognitive
      impairments in HIV infected patients comparing patients with and without HAART. Recent
      studies have demonstrated a specific HIV infected patients neurocognitive disorders profile.
      These cognitive disorders concern primarily information processing speed, memory recall,
      attentional abilities, work related memory, executive functions, and psychometrical speed.
      This cognitive profile is similar to another highly documented one, described for another
      central nervous system disease (CNS): multiple sclerosis. In both CNS diseases, the earliest
      and most severe disorder is the one related to the information processing speed. For the
      multiple sclerosis patients, a short cognitive test (SDMT) is actually used not only to
      identify cognitive disorders presence, but also in order to predict a long term disability
      worsening. A digital version of this test (CSCT), has recently been developed in order to
      make this early evaluation easier. We hypothesize that CSCT alteration would also predict
      HAND, in HIV infected patients. A complete neuropsychological assessment is highly time and
      personal consuming. This short (approximatively 2 minutes) digital test would be highly
      helpful to identify patients, who will need a more extensive neuropsychological assessment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">November 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Speed Computerized Test (CSCT) score</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>allows the evaluation of the speed of the processing of the information</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA) Score</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>allows the evaluation of the overall cognitive functioning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Paced Auditory Serial Addition Test (PASAT) score</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>allows to evaluate the concentration capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Memory (WAIS-III location and back)</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>short-term memory evaluation and verbal working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score RL-RI16</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>allows the evaluation of episodic and long-term verbal memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rey figure</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>allows the evaluation of the long-term capacities of visio-construction (wealth score) and planning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMTB - TMTA Time Score</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>Assessment of Mental Flexibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal fluency test</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>allows the evaluation of the verbal initiation and verbal language capacities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IADL score</measure>
    <time_frame>at patient inclusion</time_frame>
    <description>allows to evaluate the symptomatic character of the disorders</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Absence of cognitive disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic cognitive disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic cognitive impairment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV associated dementia</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Classic evaluation of neurocognitive functions</intervention_name>
    <description>Symbol Digit Modalities Test (SDMT)</description>
    <arm_group_label>Absence of cognitive disorder</arm_group_label>
    <arm_group_label>Asymptomatic cognitive disorder</arm_group_label>
    <arm_group_label>Symptomatic cognitive impairment</arm_group_label>
    <arm_group_label>HIV associated dementia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>New evaluation of neurocognitive functions</intervention_name>
    <description>Cognitive Speed Computerized Test (CSCT)</description>
    <arm_group_label>Absence of cognitive disorder</arm_group_label>
    <arm_group_label>Asymptomatic cognitive disorder</arm_group_label>
    <arm_group_label>Symptomatic cognitive impairment</arm_group_label>
    <arm_group_label>HIV associated dementia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with HIV-1
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients infected with HIV-1

          -  Patients followed in outpatient service, over 18 years of age

        Exclusion Criteria:

          -  Patients infected with HIV-2

          -  Patients with difficulty understanding the French language

          -  Patients present with progressive opportunistic infection

          -  Patients for whom a change of psychotropic treatment was performed in the last 3 weeks

          -  Patients with drug and / or alcohol addiction

          -  Patients with a history of psychiatric disorder

          -  Patients with stroke, endocarditis or meningoencephalitis with severe neurological
             sequelae
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Christine Lebrun-Frenay, PU-PH</last_name>
    <phone>+33 (0)4.92.03.85.27</phone>
    <email>lebrun-frenay.c@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Pasteur 2 - Service de Neurologie</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Lebrun-Frenay, Pu-PH</last_name>
      <phone>+33 (0)4.92.03.85.27</phone>
      <email>lebrun-frenay.c@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

